Along with the rest of the market, Novo Nordisk (NYSE:NVO) has been sinking this year – with losses approaching 30% year-to-date. The skid for the Danish biopharma company started awhile back ...

Novo Nordisk has filed 111 lawsuits in 32 states to stop the sale of dangerous, mislabeled, or impurity-laden knockoff semaglutide drugs. Feel unsure about the market’s next move? Copy trade ...

Novo Nordisk scored a huge legal victory that largely restricts compounding pharmacies from marketing or selling cheaper, unapproved versions of the drugmaker's blockbuster weight loss drug Wegovy ...

Novo Nordisk (NYSE: NVO), the Danish drugmaker of GLP-1 weight loss drugs Ozempic and Wegovy, slipped 2% through 10:30 a.m. ET Friday after suffering a one-two punch from Reuters and a bank analyst.

In a move which could shake up the diabetes market, Novo Nordisk is discontinuing the country’s largest selling insulin, Human Mixtard, among other older insulin brands in India. Human Mixtard ...

Novo Nordisk (NVO) won a key case Thursday to stop some compounding pharmacies from selling knockoff versions of its blockbuster GLP-1 drugs. But it won't end all compounding offerings.

LONDON (Reuters) - Since launching its wildly popular weight-loss drug Wegovy in 2021, Novo Nordisk (NYSE:NVO) has raised its annual sales guidance several times a year. But recent weak U.S ...

LONDON (Reuters) - Since launching its wildly popular weight-loss drug Wegovy in 2021, Novo Nordisk has raised its annual sales guidance several times a year. But recent weak U.S. prescription data is ...

Novo Nordisk will invest around $1 billion to expand its production site in Montes Claros, Brazil, marking one of the largest pharmaceutical investments in the nation’s history. The company’s ...